PriceTargets.com logo

Actinium Pharmaceuticals - ATNM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $7.40
  • Forecasted Upside: 473.64%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.29 As of 12/20/2024 06:31 PM ET
▲ +0.17 (15.18%)

This chart shows the closing price for ATNM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Actinium Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATNM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATNM

Analyst Price Target is $7.40
▲ +473.64% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Actinium Pharmaceuticals in the last 3 months. The average price target is $7.40, with a high forecast of $21.00 and a low forecast of $2.00. The average price target represents a 473.64% upside from the last price of $1.29.

This chart shows the closing price for ATNM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in Actinium Pharmaceuticals. This rating has held steady since July 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2024StephensReiterated RatingOverweight ➝ Overweight$5.00 ➝ $5.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
8/7/2024B. RileyDowngradeBuy ➝ Neutral$16.00 ➝ $2.00
8/6/2024HC WainwrightLower TargetBuy ➝ Buy$50.00 ➝ $4.00
8/6/2024Maxim GroupLower TargetBuy ➝ Buy$30.00 ➝ $5.00
7/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
6/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
5/14/2024StephensInitiated CoverageOverweight$25.00
4/30/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$21.00
4/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$21.00
3/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
3/19/2024Maxim GroupBoost TargetBuy ➝ Buy$20.00 ➝ $30.00
3/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00
12/11/2023B. RileyLower TargetBuy ➝ Buy$20.00 ➝ $16.00
10/3/2023B. RileyReiterated RatingBuy ➝ Buy$20.00
9/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
9/6/2023HSBCInitiated CoverageBuy$11.60
8/15/2023HC WainwrightLower TargetBuy ➝ Buy$53.00 ➝ $50.00
4/20/2023HC WainwrightReiterated RatingBuy$53.00
4/4/2023Cantor FitzgeraldBoost Target$26.00 ➝ $27.00
2/21/2023HC WainwrightReiterated RatingBuy$53.00
2/21/2023William BlairDowngradeOutperform ➝ Market Perform
2/7/2023HC WainwrightReiterated RatingBuy$53.00
10/31/2022B. RileyBoost TargetBuy$16.00 ➝ $18.00
10/31/2022HC WainwrightBoost TargetBuy$45.00 ➝ $53.00
10/31/2022Maxim GroupBoost Target$25.00 ➝ $35.00
9/8/2022Cantor FitzgeraldInitiated CoverageOverweight$20.00
8/25/2022B. RileyInitiated CoverageBuy$16.00
4/12/2022HC WainwrightReiterated RatingBuy$45.00
10/6/2021Maxim GroupReiterated RatingBuy$25.00
9/15/2021Alliance Global PartnersBoost TargetBuy$20.00 ➝ $25.00
8/3/2021HC WainwrightLower TargetBuy$57.00 ➝ $45.00
4/1/2021HC WainwrightLower TargetBuy$65.00 ➝ $57.00
3/10/2021HC WainwrightReiterated RatingBuy$65.00
12/31/2020William BlairReiterated RatingBuy
12/7/2020HC WainwrightReiterated RatingBuy$65.00
12/4/2020William BlairReiterated RatingBuy
11/5/2020Alliance Global PartnersInitiated CoverageBuy$25.00
8/21/2020Maxim GroupReiterated RatingBuy
6/4/2020HC WainwrightReiterated RatingBuy
6/4/2020HC WainwrightInitiated CoverageBuy$90.00
4/17/2020Maxim GroupInitiated CoverageBuy$45.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 6 very positive mentions
  • 24 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 5 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Actinium Pharmaceuticals logo
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
Read More

Today's Range

Now: $1.29
Low: $1.13
High: $1.29

50 Day Range

MA: $1.56
Low: $1.12
High: $1.94

52 Week Range

Now: $1.29
Low: $1.10
High: $10.24

Volume

1,083,387 shs

Average Volume

438,404 shs

Market Capitalization

$40.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Actinium Pharmaceuticals?

The following equities research analysts have issued research reports on Actinium Pharmaceuticals in the last year: B. Riley, Cantor Fitzgerald, HC Wainwright, Maxim Group, Stephens, and StockNews.com.
View the latest analyst ratings for ATNM.

What is the current price target for Actinium Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Actinium Pharmaceuticals in the last year. Their average twelve-month price target is $7.40, suggesting a possible upside of 473.6%. Cantor Fitzgerald has the highest price target set, predicting ATNM will reach $21.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $2.00 for Actinium Pharmaceuticals in the next year.
View the latest price targets for ATNM.

What is the current consensus analyst rating for Actinium Pharmaceuticals?

Actinium Pharmaceuticals currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ATNM.

What other companies compete with Actinium Pharmaceuticals?

Other companies that are similar to Actinium Pharmaceuticals include Adaptimmune Therapeutics, Puma Biotechnology, Elutia, Black Diamond Therapeutics and Instil Bio. Learn More about companies similar to Actinium Pharmaceuticals.

How do I contact Actinium Pharmaceuticals' investor relations team?

Actinium Pharmaceuticals' physical mailing address is 100 PARK AVE., 23RD FLOOR, NEW YORK, NY, 10017. The company's listed phone number is (646) 677-3870 and its investor relations email address is [email protected]. The official website for Actinium Pharmaceuticals is actiniumpharma.com. Learn More about contacing Actinium Pharmaceuticals investor relations.